HiPP GmbH & Co. Vertrieb KG
9
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
22.2%
2 terminated/withdrawn out of 9 trials
77.8%
-8.7% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Prevention of Allergic Diseases in Infants
Role: lead
Effect of an Infant Formula With Synbiotics in Infants Born Via Caesarean Section
Role: lead
Evaluation of Safety and Efficacy of New Infant Formula in Infantile Colic
Role: lead
The Combiotic-Study
Role: lead
Safety of an Infant Formula With Hydrolysed Protein in Term Infants
Role: lead
Atopic Dermatitis in Atopy Predisposed Infants
Role: lead
Formula With Modified Content of Protein and Improved Fatty Acids and Their Impact on Infant Growth and Health
Role: collaborator
Suitability of an Infant Formula With L-5-Methyltetrahydrofolate for the Particular Nutritional Use in Infants
Role: collaborator
Low-protein Infant Formula With Partial or Extensive Proteinhydrolysate 4 Year Follow-up
Role: lead
All 9 trials loaded